	US 11,987,601 B2
	Norovirus fusion proteins and VLPs comprising norovirus fusion proteins
Pierre-Olivier Lavoie, Quebec (CA); and Marc-Andre D'Aoust, Quebec (CA)
Assigned to ARAMIS BIOTECHNOLOGIES INC., Quebec (CA)
Filed by ARAMIS BIOTECHNOLOGIES INC., Quebec (CA)
Filed on May 3, 2022, as Appl. No. 17/735,706.
Application 17/735,706 is a division of application No. 16/496,244, granted, now 11,608,361, previously published as PCT/CA2018/050352, filed on Mar. 23, 2018.
Claims priority of provisional application 62/475,660, filed on Mar. 23, 2017.
Prior Publication US 2023/0024533 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); C07K 16/10 (2006.01); C12N 7/00 (2006.01); C12N 15/82 (2006.01); A61K 9/00 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); C07K 16/10 (2013.01); C12N 7/00 (2013.01); C12N 15/8257 (2013.01); A61K 9/0019 (2013.01); C07K 2319/00 (2013.01); C12N 2770/16022 (2013.01); C12N 2770/16023 (2013.01); C12N 2770/16034 (2013.01)]

20 Claims

1. A method of producing a norovirus VP1 fusion protein in a plant, a portion of the plant, or a plant cell comprising,

introducing into the plant, the portion of the plant, or the plant cell a nucleic acid comprising a first sequence encoding an S domain derived from a first norovirus strain and a second sequence encoding a P domain derived from a second norovirus strain, the first norovirus strain selected from norovirus genotypes GI.1, GI.5, GII.1, GII.12, GII.14, and GII.21, and the second norovirus strain selected from norovirus genogroups GI, and GIV or selected from norovirus genotypes GII.1, GII.2, GII.3, GII.4, GII.5, GII.7, GII.12, GII.13, GII.14, GII.17 and GII.21, and

incubating the plant, the portion of the plant, or the plant cell under conditions that permit the expression and production of the norovirus VP1 fusion protein.